Introduction
============

Ischemic stroke is a leading cause of death and disability in the United States with limited therapeutic interventions available, including tissue plasminogen activator (t-PA) and endovascular mechanical thrombectomy ([@B85]; [@B6]; [@B84]). These interventions are focused on the removal of the thrombus, restoring blood flow, oxygen and glucose to hypoperfused areas, but are unable to affect the inflammatory, necrotic, and blood-brain barrier (BBB) mechanism that follow. In particular, the initial inflammatory cascade is initiated by the decrease in ATP production, release of cytokines, influx of intracellular calcium, reactive oxygen species, etc., that develops during occlusion and continues for days afterward ([@B90]). Using shear forces from cerebral blood flow, marrow-derived leukocytes (including polymorphonuclear leukocytes (PMNs), neutrophils, lymphocytes and monocytes) are recruited to the site of injury ([@B28]; [@B27]; [@B102]).

For the purpose of this review, we will focus on the recruitment and rolling of leukocytes under the direction of integrins, as well as some of their ligands following reperfusion after ischemic stroke. We will then introduce recent β~2~ and β~1~ integrin-specific stroke clinical trials, and, finally, discuss potential future directions for the field.

Leukocytic Infiltration Following Ischemic Stroke
=================================================

Leukocyte Recruitment
---------------------

The initial endothelial response upregulates endothelial selectins, particularly P-selectin and E-selectin, translocating them from an intracellular, inactive state, to the available extracellular matrix for leukocytic binding, while the upregulation of L-selectin on the leukocyte is essential for recruitment to the site of injury ([@B4]). Both are acutely regulated, P-selectin at 15 min and E-selectin at 2 h post ischemia. These extracellularly located selectins then facilitate the recruitment and activation of leukocytes to the area of ischemia ([@B119]). Leukocytes then undergo a conformational change, facilitating polarization and the development of certain cellular characteristics: a leading edge, main body, and rear-uropod protrusion. The uropod, or posterior protrusion, in fast moving leukocytes promotes mobility, while the leading protrusions (lamellipodia and filopodia, small leg-like projections) are less likely to be used due to the rate limiting interaction with actin filaments ([@B87]) (summarized in [Figure 1](#F1){ref-type="fig"}). Though this mechanism is less obvious in the highly mobile leukocytes. Once leukocytes are bound to selectins, additional binding to integrins and adhesion molecules (intracellular adhesion molecule (ICAMs and vascular adhesion molecule-1 (VCAM) occurs, permitting leukocytic rolling ([@B26]; [@B67]; [@B53]; [@B5]). Additional damage can occur once at the site of ischemia, as infiltration into the brain parenchyma across the BBB destroys surrounding vasculature ([@B22]; [@B21]), and leukocytes continually release additional factors (reactive oxygen species, cytokines, and proteases) that enhance leukocytic recruitment ([@B114]).
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Leukocyte Infiltration
----------------------

At the site of injury, leukocytes continue to increase binding on cerebrovasculature up to 48 h following ischemic stroke, and use transendothelial migration as a method for infiltration from the cerebrovasculature into the surrounding brain parenchyma. Early adhesion, prior to 24 h following reperfusion, is attributed to neutrophils. Within 30 min to a few hours following reperfusion, neutrophils arrive at the site of injury, peaking at maximum expression around 1--3 days, though expression can still be detected 7--15 days later in preclinical stroke models ([@B115]). This upregulation is also seen in ischemic stroke patients, where neutrophils have been detected beginning at 6 h, with radiolabeled imaging, and continue to be detected up to 72 h ([@B3]). The early recruitment and infiltration of neutrophils across the BBB appears to be highly significant in stroke, as high neutrophilic infiltration is associated with damaged cerebrovasculature ([@B33]), while depletion reduces infarct volume and dysfunction in stroke models ([@B21]).

As reperfusion injury continues, the circulating leukocytes switch from neutrophils to mononucleuar leukocytes (monocytes/lymphocytes) which dominate the adherent culture from 24 h to 7 days post reperfusion ([@B96]; [@B104]; [@B46]). Of the two types of lymphocytes, B- and T-, T cells have emerged as the dominant, damage-inducing lymphocyte in ischemic stroke ([@B11]). Preclinical studies have shown that the inhibition of all lymphocytes results in smaller infarct and improved neurological outcomes, but only the reintroduction of T-lymphocytes to mice reversed any benefits ([@B117]; [@B54]). Activated T-lymphocytes, not B-, have been detected in patients up to 60 days post-stroke, and are correlated with an increased risk of stroke reoccurrence and death ([@B107]; [@B74]).

Clinical Importance of Leukocytes
---------------------------------

Multiple studies have established the importance of leukocytic adherence and infiltration into the brain parenchyma following ischemic stroke, but targeting the leukocytes has a high degree of risk. This is evident as inhibition of leukocytic cells increase the occurrence of bacterial infection and mortality as evident by Leukocytic Adhesion Deficiency (LAD-1) ([@B102]). Because these cells are necessary for bacterial resistance, systemic inhibition following ischemic stroke is exceptionally risky. However, studies in stroke patients show a strong correlation between increased levels of peripheral leukocytes and neutrophils, and increased infarct volume ([@B83]; [@B12]). Thus, some current therapeutic strategies have focused on the inflammatory cascade have focused on blocking the adhesion and infiltration of cells at the site of injury, primarily endothelial expressed ICAMs and VCAM. This method has shown success in preclinical studies, but has failed to translate to the clinic. Thus, the focus has switched to directly targeting the integrins, a primary mediator of leukocyte adhesion, rather than their ligands, as discussed above. This review is focused on integrins β~2~ and β~1~ that have shown promise in therapeutically targeting the ischemic stroke inflammatory cascade.

Role of Integrins Post-Stroke: an Overview
==========================================

Integrins are a diverse group of heterodimers composed of 18 different α and β subunits, creating 24 unique combinations. Integrins exist on every cell type, while exhibiting a high diversity of ligands and grouped into four different receptor groups: RGD (Arg-Gly-Asp), laminin receptors, collagen receptors, and leukocyte-specific receptors. Within these groups, integrins can have a variety of ligands and roles following ischemic stroke (reviewed in [@B30]). Under normal cerebrovascular conditions, integrins are in a highly inactive state, typically in a bent conformation ([@B106]; [@B76]). Following ischemic stroke, activation signals are sent. Chemokines are translocated to the lumen, on the apical side of endothelial cells, to induce "inside-out" signaling ([@B18]). Integrins then undergo a conformational change to increase integrin affinity for potential ligands while enhancing detection by localizing to the leading or rear-facing edge of the leukocyte's cell wall for ligand detection ([@B87]; [@B45]). Activated integrins then bind to available ligands, permitting leukocytic rolling and intracellular signaling. This is termed "outside-in" signaling ([@B42]; [@B109]; [@B60]). Leukocytes continue movement to the site of injury, looking for areas to cross the endothelial cell barrier, and eventually coming to a halt. Aggregation/clustering of integrins increases binding avidity (strength of binding), preventing flow conditions from detaching leukocytes from the endothelial cells ([@B60]). Using transmigration, leukocytes will infiltrate into the cerebral parenchyma using these integrin-ligand connections.

β~2~ Integrins
--------------

β~2~ integrins are the only group of integrins exclusively expressed on leukocytes (derived from hematopoietic cells) ([@B94]), and like most integrins, are highly conserved across species ([@B95]). They are also the most highly expressed integrin on circulating blood leukocytes, tending to cluster at the retraction area of the cell (the rear), in both an active and inactive state, compared to other β~1~, β~4~, β~3~, and β~7~ integrins found on circulating leukocytes ([@B81]; [@B63]). Genetic leukocyte adhesion changes (LAD-1, as discussed above) has been attributed to mutations in the β~2~ subunit, reducing β~2~ expression. Thus, leukocytic movement is reduced on the cell surface with less movement toward the site of inflammation ([@B1]; [@B93]). Importantly, in β~2~ inhibited mice, there is not total arrest of leukocytic recruitment or infiltration ([@B81]), suggesting that other factors likely play a role. There are 4 identified heterodimers of β~2~ integrins, and of these, the most highly studied are α~*L*~β~2~ and α~*M*~β~2~ in ischemic stroke, and will be reviewed in more detail below. The other β~2~ integrins, α~*X*~β~2~ and α~D~β~2~, have not been individually studied in the context of stroke as have α~*L*~β~2~ and α~*M*~β~2~ integrins, though CD18 (β~2~) inhibition in addition to t-PA has been shown to increase the time window of t-PA administration without an increase in hemorrhagic transformation in a rat embolic stroke model ([@B120]). Furthermore, [Figure 2](#F2){ref-type="fig"} summarizes the results in this section.
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### α~*L*~β~2~ Integrin

Integrin α~*L*~β~2~ is also referred to as CD11a/CD18 and LFA-1 (lymphocyte functional-associating antigen-1). α~*L*~β2 integrin acutely increases in ischemic stroke patients, with detectable amounts through 72 h associated around the area of ischemia ([@B35]; [@B122]). This suggests a correlation between α~*L*~β~2~ integrin expression and inflammatory damage following ischemia. α~*L*~β~2~ is expressed on all leukocytes ([@B99]), though at particularly high levels on T-lymphocytes ([@B40]; [@B113]). In healthy individuals, extracted blood analysis revealed that α~*L*~β~2~ activation requires leukocytic rolling on P- or E-selectins, inducing an active conformational change ([@B56]), but it is the binding of chemokines g-protein coupled receptors (GPCR) and Rap-1 activation that induces the high-affinity conformational state of α~*L*~β~2~ ([@B103]; [@B38]; [@B36]). In this state, α~*L*~β~2~ has many possible ligands, ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5, and junctional adhesion molecule-1 (JAM-1) ([@B70]; [@B25], [@B24]; [@B108]), though ICAM-1 is preferentially bound ([@B113]). The high avidity α~*L*~β~2~-ICAM-1 complex, once formed, allows t-lymphocytes to move against circulatory flow and the shear forces, resulting in the high-speed movement of leukocytes ([@B51]; [@B29]).

In an intraluminal model of experimental ischemic stroke, α~*L*~β~2~ inhibition with the use of transgenic mice results in reduced infarct volume, edema volume and mortality. However, this phenomenon is evident in transient, but not permanent middle cerebral artery occlusion ([@B2]). This may be due to the previously mentioned high avidity of α~*L*~β~2~-ICAM-1 bonds, and is evident in an *in vitro* study using α~*L*~β~2~ (LFA-1) knock-in mice that experience high avidity through binding of lymphocytes mediated through ICAM-1 binding, but are unable to continue movement due to a non-polarized uropod ([@B80]). An explanation for this phenomenon may be that the recycling process within the leukocyte is overwhelmed ([@B97]). By enhancing α~*L*~β~2~ expression, recycling may not be able to allow for dislocation of α~*L*~β~2~-ICAM-1 complexes, preventing movement from the loss of high adhesion bonds. Enhanced α~*L*~β~2~ expression could be a potential new avenue for therapy, especially if no enhanced mortality, infection, etc., are observed.

Independently, ICAMs play a significant role in inflammation following ischemic stroke. ICAM-1, in particular, is acutely increased in both cultured human endothelial cells undergoing hypoxia and following intraluminal suture middle cerebral artery occlusion, while expression remains sustained for up to a week post-injury ([@B43],[@B44]; [@B121]). ICAM-2, another possible ligand, does not change in expression following cytokine stimulation ([@B25]; [@B77],[@B78]). Furthermore, serum of ischemic stroke patients contains soluble ICAM-1, but not ICAM-2 in addition to being a risk factor ([@B50]; [@B98]). Antibodies targeting ICAM-1 in rodents and humans have shown contradictory results. An intraluminal suture middle cerebral artery occlusion model in mice and rats showed a decrease in leukocyte infiltration and infarct volume ([@B23]; [@B52]; [@B111]), while one study reported opposing effects ([@B34]). ICAM-1 inhibition was translated to the clinic through testing of the murine ICAM-1 antibody, Enlimomab in ischemic stroke. Unfortunately, the study was halted early due to increased rate of infection, infarct volumes, neurological scores and mortality for patients ([@B34]).

### α~*M*~β~2~ Integrin

Integrin α~*M*~β~2~, also known as CD11b/CD18 and Mac-1 (macrophage-1 antigen)~,~ exhibits many similarities to α~*L*~β~2~ through its expression on all leukocytes ([@B100]), and common ligand binding partners such as the family of ICAMs and JAMs ([@B112]). Additional ligands are fibrinogen, heparin ([@B112]), elastase ([@B13]), complement C3 fragment (C3bi) ([@B71]), kinogen components, and urokinase and its receptor ([@B19]). Just as α~*L*~β~2~, hypoxia induced factors (cytokines, chemokines, etc.) induce conformational change of α~*M*~β~2~ to a high affinity ligand-binding state ([@B101]). Binding assays with ICAM-1 as a ligand and both α~*L*~β~2~ and α~*M*~β~2~ as receptors show α~*L*~β~2~ integrin is preferably bound ([@B68]). This suggests that the binding sites on both α~*L*~β~2~ and α~*M*~β~2~ compete for ICAM-1 binding.

Following experimental ischemic stroke in rats, integrin α~*M*~β~2~ is upregulated ([@B15]), and has shown benefit when inhibited. Antibodies against both CD11b/CD18 reduce infarct volume and reestablish cerebral blood flow as a result of decreased neutrophil infiltration following intraluminal stroke surgery ([@B20]; [@B10]; [@B121]). In a different approach, the addition of recombinant neutrophil inhibitory factor (rNIF) inhibits a binding domain on Mac-1 and yields similar results in the same intraluminal occlusion model ([@B47]). Furthermore, and similarly to α~*L*~β~2~ integrin inhibition, inhibition of α~*M*~β~2~ is also effective in transient, but not permanent experimental ischemic stroke in an embolic occlusion model ([@B118]).

β~1~ Integrins
--------------

β~1~ integrins are a diverse set of integrins, with laminin-binding, collagen-binding, RGD-binding and leukocyte heterodimers. β~1~ integrins are not as highly expressed on leukocytes as β~2~ integrins, but they do play a major role in leukocyte adhesion and migration following ischemic stroke. The activity of β~1~ integrins is similar to β~2~ integrins. They undergo a conformational change to induce "inside-out" and "outside-in" cellular signaling ([@B16]). As the cells migrate, the β~1~ integrins are most commonly clustered around the uropod, but will be located in any area of the leukocyte that is in contact with the endothelial cell or extracellular matrix ([@B16]; [@B14]). Inhibition of the β~1~ integrin, just as with β~2~ integrin inhibition, does not fully stop leukocyte rolling. However, when both β~1~ and β~2~ integrins are inhibited, complete leukocyte arrest occurs ([@B65]; [@B81]). This suggests that both β~1~ and β~2~ integrins are necessary for leukocyte migration, regardless of expression load. Of all the β~1~ integrins, both α~4~β~1~ and α~5~β~1~ appear to be the most highly expressed and the most studied in post-stroke inflammation. The other β~1~ integrin expressed on leukocytes, α~9~β~1~, has not been studied in the context of stroke as its expression and role has not yet been fully elucidated in the brain. [Figure 3](#F3){ref-type="fig"} summarizes the results discussed in this section.
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### α~4~β~1~ Integrin

α~4~β~1~, also known as CD49d/CD29 VLA-4 (very late antigen-4)~,~ is localized primarily to leukocytes (neutrophils, monocytes, lymphocytes, macrophages, etc.) and microglia as a leukocyte-specific receptor. Additionally, α~4~ will also dimerize with β~4~, which is found in gut endothelium ([@B40]). Activation of α~4~β~1~ integrin results from the binding of upregulated chemokines to GPCRs in the same manner as α~*L*~β~2~ as discussed above ([@B110]). This stimulates binding to α~4~β~1~'s preferred ligand, VCAM-1, but experiments have shown some preference for paxillin ICAM-1 ([@B103]; [@B36]), and fibronectin ([@B41]) as well. Interestingly, instead of using the β~1~ submit of the heterodimer for binding, integrin α~4~β~1~ uses its α subunit of α~4~β~1~ to mediate binding to VCAM-1 ([@B69]).

Preclinical ischemic stroke studies targeting α~4~β~1~ have shown increasingly varied results. Most researchers reported a decrease in VCAM-1 expression, cytokine production, and infiltrating leukocytes ([@B62]; [@B58]; [@B64]), but this reduction in inflammation did not result in reduced infarct volumes or functional deficit following analysis of a randomized preclinical trial involving six different centers ([@B64]). Langhauser et al went one step further and found that no treatment paradigm (prophylactic or therapeutic) and no model (transient or permanent) showed efficacy ([@B58]). On the other hand, both [@B5] and [@B86] found that inhibition of α~4~ improved both infarct volumes and functional deficits. When a preclinical randomized control trial was implemented at multiple centers, researchers found efficacy only in patients with small infarct volumes ([@B64]). Collectively, these contradictory results may be caused by a couple of scenarios, 1) the varying expression of integrin α~4~β~1~ expression following ischemic stroke resulting in continued leukocyte infiltration, or 2) integrin α~4~β~1~ is not a primary driver of post-stroke pathophysiology, but other factors, including other integrins, promote leukocyte migration ([@B40]).

### α~5~β~1~ Integrin

α~5~β~1,~ also known as CD49e/CD29 and VLA-5, plays an as yet largely undetermined role in inflammation, with studies primarily limited to cell culture. What is known is that leukocytes express different β~1~ integrins with α~5~β~1~ composing around 50% of all β~1~ --integrins expressed on neutrophils ([@B81]) and monocytes ([@B79]). Additionally, α~5~β~1~ is necessary for leukocyte adhesion. Only inhibition of both α~5~β~1~ and β~2~ integrins completely blocks adhesion *in vitro* ([@B81]), while inhibition of α~5~β~1~ alone prevents transmigration across the BBB ([@B57]) *in vitro*. As an RGD receptor, fibronectin has been shown to be the primary and preferred \[over other potential ligands such as fibrinogen ([@B105])\] ligand for α~5~β~1~ on endothelial cells and leukocytes ([@B92]; [@B8]). Importantly, in the presence of activated α~L~β~2,~ leukocyte α~5~β~1~ binding to fibronectin is enhanced ([@B9]; [@B66]; [@B39]). α~5~β~1~ integrin expression is induced by cytokines, particularly TNFα ([@B61]) toward the leading edge of the cell in contrast with other integrins at the uropod ([@B81]). Furthermore, α~5~β~1~ integrin appears to be highly sensitive to calcium ([@B81]), an ion that is increased rapidly following reperfusion ([@B90]). Upon calcium buffering, α~5~β~1~ expression moves from the front of the cell to the uropod and the leukocyte becomes elongated. The change in expression localization and morphology is attributed to non-movement as the leukocyte cannot detach α~5~β~1~ from the vascular wall ([@B81]). Recently, [@B31] found that inhibition of α~5~β~1~ integrin by the small peptide ATN-161 prevented CD45+ leukocytes from infiltrating the brain parenchyma following the tandem/transient common carotid artery/middle cerebral artery occlusion model. Additionally, mice were observed to have reduced BBB permeability, functional deficits, edema, and infarct volume following middle cerebral artery occlusion ([@B88]; [@B31]). Thus, targeting α~5~β~1~ after ischemic stroke could be a new avenue for reduction of inflammation following ischemic stroke.

Clinical Implications
=====================

The preclinical studies discussed here point towards the potential of targeting β~2~ and β~1~ integrins in the treatment of post-stroke inflammation. Though their potential has not fully been elucidated, many clinical trials, not just limited to stroke, have been approved in the last 10 years targeting these integrins.

The most common target for post-stroke inflammation are the β~2~ integrins. Though some efficacy has been reported, no clinical stroke trials to date have targeted the α~L~ subunit in stroke patients. However, one clinical trial with the monoclonal antibody, Efalizumab, has shown promise in decreasing T-lymphocyte rolling in patients with moderate-severe plaque psoriasis ([@B59]).

In preclinical studies targeting α~*M*~β~2~, a hookworm isolated recombinant glycoprotein targeting rNIF (UK279276) ([@B118]) and humanized Hu23F2G (Leukarrest) ([@B116]), were both shown to decrease infarct volume and increase functional recovery following reperfusion. Both therapies had negligible side effects in Phase 1 studies and thus were continued to a Phase II study, respectively, before the trials were halted due to no observed efficacy ([@B5]; [@B55]). The failure to target α~*M*~β~2~ integrin may be due to the observation that human ischemic stroke patients do not experience the increase in α~*M*~β~2~ expression as seen in rodent stroke models ([@B14]). Interestingly, when given in conjunction with United Kingdom279276, patients experienced a slight improvement ([@B55]), but no follow-up has been conducted. This interesting effect may be worth additional investigation in future clinical trials.

Clinical inhibition of β~1~ integrins, on the other hand, is small and varied. Of the current clinical trials, one trial has emerged targeting α~4~β~1~ in the context of ischemic stroke. The monoclonal antibody targeting the α~4~ subunit (Natalizumab) has been successful in protecting patients from relapses in multiple sclerosis ([@B82]) and Crohn's disease ([@B89]). However, in a Phase II ischemic stroke study, patients receiving Natalizumab showed no improvement in infarct growth or neurological scores over 30 days. Furthermore, two patients (out of 79) died from serious infections attributed to Natalizumab treatment ([@B32]). At this time, there are no further clinical trials planned.

Future Considerations
=====================

As discussed in this review, targeting leukocytic integrins has had limited to no efficacy in clinical trials. Importantly, these studies have collectively employed only three different therapeutics and two targets; there are still significant areas that can be investigated. Though not discussed here, most preclinical investigations have focused on the ligands themselves rather than the integrin as the therapeutic target, highlighting the continued importance of integrins in stroke.

It is also important to note that preclinical studies carried out in rodents inadequately model the post-stroke pathophysiology that patients experience. Preclinical stroke research is also typically limited, focusing on one species, sex, and age that do not necessarily match the demographic of stroke patients (see [@B49] for a review of this topic). Furthermore, as the changes following stroke and/or reperfusion are inadequately understood, identifying appropriate therapeutic targets that translate from the lab to clinical trials, has been particularly challenging.

However, this does not suggest abandoning therapeutic trials for ischemic stroke. As mentioned above, stroke is a leading cause of death and disability, separate from cardiovascular disease. This will not improve without intervention with our aging and obese population. Fortunately, with the advent of stroke mortality-altering therapies, i.e., t-PA and endovascular mechanical thrombectomy, our financial burden has shifted to aftercare. When we review the amount of trials performed for thrombolytic agents ([@B73]; [@B75]; [@B72]) and endovascular thrombectomy \[MR CLEAN ([@B7]), ESCAPE ([@B37]), EXTEND IA ([@B17]), SWIFT PRIME ([@B91]), and REVASCAT ([@B48])\] as potential treatments of ischemic stroke, it is obvious that the complexities of stroke affect the outcome of the clinical trial. This includes, but is not limited to, the time a patient takes to arrive at an ER, time to treatment, location of the stroke, amount of surrounding collaterals, current medications and co-morbidities (diabetes, cancer, etc.), and if the patient has experienced multiple strokes.

Based on current advances, as well as previous failures, a focus on integrins as a therapeutic target for stroke is emerging. A significant reason for this focus may be the complex, multi-dimensional role that integrins appear to play in brain pathophysiology. Integrins are diverse, existing on all cell types with varying roles depending upon expression and activation. This complexity can represent a significant challenge to integrin-targeted therapies inasmuch as such therapies could have diverse, even unintended off-target effects. However, we believe that this can be overcome by a better understanding of how integrin function and expression is altered after stroke, with the potential to exploit stroke-dependent integrin changes to therapeutic effect. For example, identifying a specific integrin to be upregulated in select cells in the post-stroke brain or brain-targeting cells, but not in other organs, could render it a viable therapeutic target. This emphasizes the need and importance of preclinical stroke research to discover and unravel the complexities of integrin biology. We are confident that such studies will result in viable new stroke therapies.

Conclusion
==========

In this review, we have implicated integrins as an area of research for limiting inflammation following ischemic stroke. To date, therapeutic inhibition of α~*L*~β~2~, α~*M*~β~2~, and α~4~β~1~ has shown promising results in preclinical studies, but translation to the clinic has been disappointing. Going forward, more targeted antibodies to all reactive β~1~ and β~2~ integrins after ischemic stroke may prove more beneficial, but more research needs to be done to completely understand the human inflammatory response and how that relates to changes in preclinical models.
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